CLNN - IBN Announces First in Human Podcast Featuring Clene Inc. CEO Rob Etherington | Benzinga
LOS ANGELES, March 19, 2024 (GLOBE NEWSWIRE) -- via IBN – IBN, a multifaceted communications organization engaged in connecting public companies with the investment community, today announces that Rob Etherington, President, Director and CEO of late clinical-stage biopharmaceutical company Clene Inc. (NASDAQ:CLNN), recently appeared on First in Human, a biotech-focused podcast featuring interviews with industry leaders and investors to learn about their journeys to in-human clinical trials.
The podcast, hosted by Vial EVP, Rich McCormick, is available for on-demand listening on First in Human by Vial.
During the interview, Etherington highlighted information about Clene's work in the field of nanotechnology.
"For decades…the idea of a therapeutic elemental metal having some medicinal efficacy has been well understood. We at Clene had the idea to combine this with the mechanism of a nanotherapeutic, providing, at the atomic level, the ability to drive energy into the failing mitochondria that powers your and my brain. We had the idea to do that with a catalytically active nanotherapeutic suspension, which the patients drink daily."
"We first completed some translational medicine work, whereby we were able to show that our drug taken orally got into the stomach then into ...